An observational study in Advanced Parkinson Disease, sponsored by Britannia Pharmaceuticals Ltd.. Active, not recruiting at 57 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Britannia Pharmaceuticals Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies in Parkinson Disease with a site in Germany — 41 open to participants now, 53 under way, 2 of them phase 3. Parkinson Disease · Germany.
Among the 264 studies in Parkinson Disease with a site in Germany, this one is the 24th largest by enrollment of the 64 observational ones that give a count, is one of 11 that started in 2021, is one of 64 observational ones, reaches primary completion later than 14 of the 52 other live ones, and was the 207th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →41 of the 264 studies in Parkinson Disease with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Tuebingen · Sites in Germany, France, Italy and 4 more countries
Ages 35–80
MODAG GmbH · Sites in Germany
Ages 50–75 · Healthy volunteers
H. Lundbeck A/S · Sites in Germany, United States, Czechia and 1 more country
Ages 40–85
University Hospital Muenster · Sites in Germany
Ages 18+
Integrative Research Laboratories AB · Sites in Germany, Bulgaria, Poland and 1 more country
Ages 50–90
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 53 · Phase 3 65 · Phase 4 19
First in 2001; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 312 is above the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 106 across the 198 interventional studies, 195 across the 64 observational. Of the 186 that completed or were terminated, 73 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
173 of 264 have an industry lead sponsor. The 10 most frequent:
Britannia Pharmaceuticals Ltd. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Britannia Pharmaceuticals Ltd. has 4 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Parkinson Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07134634Parkinson's Clinic in Beelitz-HeilstattenEffect of a Vibrating Therapy Ball on Tremor and Daily Activities in Patients With Different Tremor Syndroms | 2026-11 |
| NCT06580977Heidelberg UniversityExploring the Effects of Exercise on Memory and Cognition in Parkinson´s Disease | 2026-12 |
| NCT07141719University of KielCollection of Digital Parameters From Parts of the Neurological Examination Using an Eye Tracker | 2026-12-31 |
| NCT06602193Denali Therapeutics Inc.Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | 2027-03 |
| NCT06993571Universitätsklinikum Hamburg-EppendorfCerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor | 2027-03-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 264 studies in Parkinson Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).
Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing.
In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.
Study design:
Non-interventional study, primary data collection.
No visits or measurements will be made mandatory by the observational plan. The assignment of patients to Lecigon® not decided in advance by the study's observational plan but falls within current practice. Prescription of Lecigon® occurred before and independently of the decision to include the patient in the study.
The participating centres will offer participation in the ELEGANCE study to all patients who receive treatment with Lecigon® part of routine clinical practice. From patients, who switched to treatment with Lecigon® prior to signing of informed consent, baseline data will be collected retrospectively.
The planned non-interventional study aims to collect real-world data on the effectiveness and safety of Lecigon® as a therapy for advanced Parkinson´s Disease in routine care in Germany and Austria. The study will be expanded to additional European countries as soon as marketing authorisation in these countries and commercial stock will be available.
Primary Objectives:
Secondary Objectives:
Treating physician's normal patient pool
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There might be different brand names in other countries
Change in OFF time from baseline up to 24 months, or treatment or study discontinuation
To assess the effectiveness of Lecigon® treatment on the change in OFF time (h/day) from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale IV Scores (MDS-UPDRS IV- motor complications)
Time frame: 24 months
Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation
To assess the effectiveness of Lecigon® treatment on the change in motor experiences of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale II Scores (MDS-UPDRS II - motor experiences of daily living)
Time frame: 24 months
Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation
To assess the effectiveness of Lecigon® treatment on the change in Daily Levodopa dose \[mg/day\] from baseline up to 24 months, or treatment or study discontinuation as measured by morning bolus, continuous flow, extra boli, oral doses
Time frame: 24 months
Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation
To assess the effectiveness of Lecigon® treatment as measured by usage of other anti-Parkinsonian medicinal products (e.g. levodopa, dopamine agonists, Monoamine Oxidase (MAO)-B inhibitors, amantadine from baseline up to 24 months, or treatment or study discontinuation
Time frame: 24 months
Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation
To assess the effectiveness of Lecigon® treatment use of programmed pump rate (2 or 3 rates) from baseline up to 24 months, or treatment or study discontinuation will be collected
Time frame: 24 months
Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation
To assess the effectiveness of Lecigon® treatment on the change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation as measured by Clinical Global Impression of Improvement Scale Score (CGI-I)
Time frame: 24 months
Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation
To assess the effectiveness of Lecigon® treatment on the change in Patient Global Impression of Change (PGI-C) from baseline up to 24 months, or treatment or study discontinuation as measured by Patient Global Impression of Change Scale Score (PGI-C)
Time frame: 24 months
Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation
To assess the effectiveness with Lecigon®, satisfaction with treatment will be assessed in terms of pump size, weight, noise, handling and overall pump satisfaction from baseline up to 24 months or treatment or study discontinuation as measured by device satisfaction scale score between 0 (absolutely unsatisfied) to 10 (absolutely satisfied) for each item.
Time frame: 24 months
Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation
To assess the long-term safety of Lecigon® treatment Adverse Events (AEs) and Serious Adverse Events (SAEs) (including drug-related, device- and procedure-related Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs), AEs of special interest) from time of Informed consent to study completion for up to 24 months or treatment or study discontinuation will be collected
Time frame: 24 months
Change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation
To assess the impact of Lecigon® treatment on the change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation as measured by Non-Motor Symptom Scale Scores (NMSS)
Time frame: 24 months
Change in Sleep Quality from baseline up to 24 months, or treatment or study Discontinuation
To assess the impact of Lecigon® treatment on the change in sleep quality from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's disease sleep Scale-2 Score (PDSS-2)
Time frame: 24 months
Change in Activities of daily living from baseline up to 24 months, or treatment or study discontinuation
To assess the impact of Lecigon® treatment on the change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale Ib Score (MDS-UPDRS Ib - non-motor experiences of daily living)
Time frame: 24 months
Change in Quality of Life from baseline up to 24 months or treatment or study discontinuation
To assess the impact of Lecigon® treatment on the change in quality of life from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's Disease Questionnaire total score (PDQ-8 or PDQ-39)
Time frame: 24 months
Usage of Healthcare resources from baseline up to 24 months, or treatment or study discontinuation
To assess the impact of Lecigon® treatment on usage of Healthcare resources as measured by additional hospitalisation due to complications out of scope of nurse support team since the last visit
Time frame: 24 months
Change in Body weight from baseline up to 24 months, or treatment or study discontinuation
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Body weight (Kg) from baseline up to 24 months, or treatment or study discontinuation
Time frame: 24 months
Change in Blood pressure from baseline up to 24 months, or treatment or study discontinuation
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Blood pressure (mmHg) from baseline up to 24 months, or treatment or study discontinuation
Time frame: 24 months
Change in Pulse from baseline up to 24 months, or treatment or study discontinuation
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Pulse (bpm) from baseline up to 24 months, or treatment or study discontinuation
Time frame: 24 months
Change in the Liver function tests from baseline up to 24 months, or treatment or study discontinuation
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Liver function tests from baseline up to 24 months or treatment or study discontinuation
Time frame: 24 months
Change in the full blood count from baseline up to 24 months, or treatment or study discontinuation
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the full blood count including B12 metabolism panel from baseline up to 24 months or treatment or study discontinuation
Time frame: 24 months
Change in the ECG from baseline up to 24 months, or treatment or study discontinuation
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the ECG from baseline up to 24 months or treatment or study discontinuation
Time frame: 24 months
Change in the Renal function tests from baseline up to 24 months, or treatment or study discontinuation
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Renal function tests from baseline up to 24 months or treatment or study discontinuation
Time frame: 24 months
Started Jul 2021 (actual). Primary completion is estimated for Oct 2026, 63 months after the start.
Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 63 months is above that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Britannia Pharmaceuticals Ltd.